Advanced Solid Malignancies

Pipeline Programs

Companies

Clinical Trials

2 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule

2100%

+ 31 programs with unclassified modality

Competitive Landscape

18 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Engine BiosciencesCA - Redwood City

1 program

CFI-402411Phase 1/21 trial

Active Trials

NCT04521413Active Not Recruiting170Est. Dec 2025

GeorgiamuneMD - Rockville

1 program

GIM122Phase 1/21 trial

Active Trials

NCT06028074Recruiting111Est. Dec 2026

AstraZenecaCAMBRIDGE, United Kingdom

13 programs

AZD1208Phase 11 trial

AZD2014Phase 13 trials

AZD2014Phase 11 trial

AZD4635Phase 11 trial

AZD5305Phase 11 trial

+8 more programs

Active Trials

NCT01588548Completed43Est. Jul 2014

NCT02583542Unknown118Est. Mar 2020

NCT02299999Active Not Recruiting1,460Est. Dec 2025

+12 more trials

Hanmi PharmaceuticalKorea - Seoul

3 programs

HM30181AK tablet + Irinotecan tabletsPhase 11 trial

HM781-36B tabletsPhase 11 trial

Active Trials

NCT00979563Completed15Est. Nov 2010

NCT00986843Completed14Est. Sep 2012

NCT01455584Completed20Est. May 2013

SandozAustria - Kundl

2 programs

HSP990Phase 11 trial

TKI258Phase 11 trial

Active Trials

NCT00879905Completed64Est. Jul 2012

NCT00669097Completed13

Oneness BiotechTaiwan - Taipei City

1 program

OB318 capsulePhase 11 trial

Active Trials

NCT02347228Unknown30Est. Dec 2024

ViiV HealthcareNC - Durham

1 program

TopotecanPhase 1

Eucure BiopharmaChina - Beijing

1 program

YH002Phase 11 trial

Active Trials

NCT04353102Completed15Est. Nov 2021

AgenusMA - Lexington

1 program

aroplatinPhase 11 trial

Active Trials

NCT00316511Completed21

BioCity BiopharmaChina - Wuxi

1 program

BC2027 for InjectionPHASE_11 trial

Active Trials

NCT07368478Recruiting180Est. Jun 2028

Bristol Myers SquibbPRINCETON, NJ

1 program

BMS-663513PHASE_11 trial

Active Trials

NCT00351325Terminated45Est. Mar 2009

NovartisBASEL, Switzerland

1 program

HSP990PHASE_1

TakedaTOKYO, Japan

1 program

MLN0128PHASE_13 trials

Active Trials

NCT02724020Completed96Est. Oct 2020

NCT01351350Completed68Est. Sep 2017

NCT01058707Completed198Est. Feb 2019

RegeneronTARRYTOWN, NY

1 program

REGN421PHASE_1

ParexelMA - Boston

1 program

SaruparibPHASE_1

GSKLONDON, United Kingdom

1 program

TopotecanPHASE_11 trial

Active Trials

NCT00295243Completed25Est. Nov 2006

Treadwell TherapeuticsON - Toronto

1 program

CFI-402411PHASE_1_2

Carrick TherapeuticsIreland - Dublin

1 program

CT7001PHASE_1_21 trial

Active Trials

NCT03363893Completed124Est. Dec 2022

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

TakedaMLN0128

AstraZenecaAZD2014

GeorgiamuneGIM122

Engine BiosciencesCFI-402411

Carrick TherapeuticsCT7001

AstraZenecaAZD2014

BioCity BiopharmaBC2027 for Injection

AstraZenecaAZD5305

AstraZenecaCeralasertib

Oneness BiotechOB318 capsule

Eucure BiopharmaYH002

AstraZenecaAZD4635

AstraZenecaMEDI9447

AstraZenecaAZD2014

AstraZenecaAZD8835

Showing 15 of 32 trials with date data

Clinical Trials (32)

Total enrollment: 3,210 patients across 32 trials

NCT02724020 TakedaMLN0128

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

Start: Jun 2016Est. completion: Oct 202096 patients

Phase 2Completed

NCT02299999 AstraZenecaAZD2014

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Start: Apr 2014Est. completion: Dec 20251,460 patients

Phase 2Active Not Recruiting

NCT06028074 GeorgiamuneGIM122

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

Start: Dec 2023Est. completion: Dec 2026111 patients

Phase 1/2Recruiting

NCT04521413 Engine BiosciencesCFI-402411

Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

Start: Aug 2020Est. completion: Dec 2025170 patients

Phase 1/2Active Not Recruiting

NCT03363893 Carrick TherapeuticsCT7001

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

Start: Nov 2017Est. completion: Dec 2022124 patients

Phase 1/2Completed

NCT02583542 AstraZenecaAZD2014

A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers

Start: Jun 2015Est. completion: Mar 2020118 patients

Phase 1/2Unknown

NCT07368478 BioCity BiopharmaBC2027 for Injection

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies

Start: Nov 2025Est. completion: Jun 2028180 patients

Phase 1Recruiting

NCT05573724 AstraZenecaAZD5305

Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies

Start: Nov 2022Est. completion: May 202416 patients

Phase 1Completed

NCT05469919 AstraZenecaCeralasertib

An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies

Start: Jun 2022Est. completion: Mar 202412 patients

Phase 1Completed

NCT02347228 Oneness BiotechOB318 capsule

Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies

Start: Sep 2020Est. completion: Dec 202430 patients

Phase 1Unknown

NCT04353102 Eucure BiopharmaYH002

A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies

Start: Apr 2020Est. completion: Nov 202115 patients

Phase 1Completed

NCT03980821 AstraZenecaAZD4635

A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies

Start: Jul 2019Est. completion: Sep 202010 patients

Phase 1Completed

NCT03736473 AstraZenecaMEDI9447

A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients

Start: Nov 2018Est. completion: Jun 20196 patients

Phase 1Completed

NCT02398747 AstraZenecaAZD2014

Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies

Start: Mar 2015Est. completion: Apr 202428 patients

Phase 1Completed

NCT02260661 AstraZenecaAZD8835

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

Start: Nov 2014Est. completion: Jul 201620 patients

Phase 1Completed

NCT01588548 AstraZenecaAZD1208

Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma

Start: Jul 2012Est. completion: Jul 201443 patients

Phase 1Completed

NCT01455584 Hanmi PharmaceuticalHM781-36B tablets

Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors

Start: Jun 2011Est. completion: May 201320 patients

Phase 1Completed

NCT01351350 TakedaMLN0128

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

Start: Feb 2011Est. completion: Sep 201768 patients

Phase 1Completed

NCT01102400 AstraZenecaMEDI-575

A Study of MEDI-575 in Patients With Advanced Solid Malignancies

Start: Mar 2010Est. completion: Nov 201222 patients

Phase 1Completed

NCT01058707 TakedaMLN0128

Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies

Start: Jan 2010Est. completion: Feb 2019198 patients

Phase 1Completed

NCT01026402 AstraZenecaAZD2014

Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

Start: Dec 2009Est. completion: Aug 2014172 patients

Phase 1Completed

NCT00997945 AstraZenecaZD4054

10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies

Start: Oct 2009Est. completion: Apr 201115 patients

Phase 1Completed

NCT00981721 AstraZenecacediranib

A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies

Start: Sep 2009Est. completion: Apr 201120 patients

Phase 1Completed

NCT00879905 SandozHSP990

A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors

Start: May 2009Est. completion: Jul 201264 patients

Phase 1Completed

NCT00979563 Hanmi PharmaceuticalHM30181AK tablet + Irinotecan tablets

Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies

Start: Jul 2008Est. completion: Nov 201015 patients

Phase 1Completed

NCT00986843 Hanmi PharmaceuticalHM30181AK tablet + Irinotecan tablets

Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102)

Start: Jun 2008Est. completion: Sep 201214 patients

Phase 1Completed

NCT00669097 SandozTKI258

Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies

Start: Apr 200813 patients

Phase 1Completed

NCT00637039 AstraZenecaAZD8931

Study of AZD8931 in Patients With Advanced Solid Malignancies

Start: Feb 2008Est. completion: Dec 201241 patients

Phase 1Completed

NCT00572364 AstraZenecaKU-0059436

Open Label, Dose Escalation Phase I Study of AZD2281

Start: Nov 2007Est. completion: Jun 200918 patients

Phase 1Completed

NCT00351325 Bristol Myers SquibbBMS-663513

A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies

Start: Sep 2007Est. completion: Mar 200945 patients

Phase 1Terminated

NCT00316511 Agenusaroplatin

Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma

Start: Mar 200621 patients

Phase 1Completed

NCT00295243 GSKTopotecan

Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies

Start: Sep 2004Est. completion: Nov 200625 patients

Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 3,210 patients

18 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.